Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity

Abstract

Objective

Elevated levels of cell-bound complement activation products (CB-CAPs) (C4d deposition on B lymphocytes (BC4d) and/or erythrocytes (EC4d)) are sensitive and specific in diagnosis and monitoring of adult systemic lupus erythematosus (SLE). Our objective was to evaluate the role of CB-CAPs for diagnosis and monitoring of pediatric-onset SLE (pSLE).

Methods

A prospective cohort study of 28 pSLE and 22 juvenile arthritis patients was conducted. SLE disease activity was determined using a clinical Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) that excluded serologies. Autoantibodies were measured using solid-phase immunoassays, C3 and C4 using immunoturbidimetry, and CB-CAPs using quantitative flow cytometry. Abnormal CB-CAPs were defined as EC4d or BC4d above the 99th percentile for healthy adults (>14 and > 60 net mean fluorescence intensity (MFI), respectively). Performance characteristics of CB-CAPs were assessed using area under the curve (AUC) for receiver operating characteristics. Linear mixed effect models evaluated the correlation between CB-CAPs and clinical SLEDAI over 6 months.

Results

BC4d yielded higher AUC (0.91 ± 0.04) than C3 (0.63 ± 0.08) and C4 (0.67 ± 0.08) (p < 0.05). Abnormal CB-CAPs were 78% sensitive and 86% specific for diagnosis of pSLE (Youden’s index = 0.64 ± 0.11). In contrast to BC4d, EC4d levels correlated with clinical SLEDAI (p < 0.01).

Conclusion

CB-CAPs (EC4d and BC4d) have higher sensitivity and specificity than low complement in pSLE, and may help with diagnosis of pSLE. EC4d could provide a useful biomarker for disease activity monitoring.

Keywords

Cell-bound complement activation products pediatric lupus

Get full access to this article

View all access options for this article.

References

Pineles

Valente

Warren

Peterson

Lehman

Moorthy

. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011; 20: 1187–1192.

Hui-Yuen

Imundo

Avitabile

Kahn

Eichenfield

Levy

. Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus 2011; 20: 952–959.

Brunner

Gladman

Ibañez

Urowitz

Silverman

. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 2: 556–562.

Hanly

Farewell

Fritzler

. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods 2010; 358: 75–80.

Sturfelt

Truedsson

. Complement and its breakdown products in SLE. Rheumatology (Oxford) 2005; 44: 1227–1232.

Wilson

Armatis

Perez

. C4 concentrations and C4 deficiency alleles in systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 600–604.

Buyon

Tamerius

Belmont

Abramson

. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 1028–1037.

Conklin

Jones

O’Malley

et al.

Post-phlebotomy stability of soluble and cellular forms of complement activation: implications in SLE diagnostic assays. Arthritis Rheumatol 2015; 67. (abstract 772).

Manzi

Navratil

Ruffing

et al.

Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3596–3604.

10.

Navratil

Manzi

Kao

et al.

Platelet C4d is highly specific for systemic lupus erythematosus. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006; 54: 670–674.

11.

Yang

Chang

Lai

Lin

Chen

. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 1083–1087.

12.

Liu

Kao

Hawkins

et al.

Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2009; 2: 300–308.

13.

Kalunian

Chatham

Massarotti

et al.

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 4040–4047.

14.

Putterman

Furie

Ramsey-Goldman

et al.

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014; 1: e000056–e000056.

15.

Kao

Navratil

Ruffing

et al.

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 837–844.

16.

Lood

Tyden

Gullstrand

et al.

Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One 2014; 9: e99386–e99386.

17.

Kao

McBurney

Sattar

et al.

Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014; 5: 510–518.

18.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

19.

Cassidy

Levinson

Bass

et al.

A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 274–281.

20.

Dervieux

Conklin

Ligayon

et al.

Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. J Immunol Methods 2017; 446: 54–59.

21.

Agmon-Levin

Damoiseaux

Kallenberg

et al.

International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73: 17–23.

22.

Petri

Kim

Kalunian

et al.

Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 2005; 353: 2550–2558.

23.

Touma

Gladman

Ibañez

Urowitz

. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011; 38: 275–284.

24.

Furie

Petri

Wallace

et al.

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143–1151.

25.

Petri

Conklin

Brady

Apilado

Dervieux

. Complement C4d split products on erythrocytes are associated with composite measure of disease activity in systemic lupus erythematosus subjects receiving methotrexate and hydroxychloroquine. Arthritis Rheumatol 2016; 68. (abstract 751).

26.

Buyon

Furie

Putterman

et al.

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Sci Med 2016; 3: e000165–e000165.

27.

Merrill

Petri

Buyon

et al.

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 2018; 5: e000263–e000263.

28.

Shields

Mollnes

Eidet

et al.

Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases. PLoS One 2017; 12: e0174577–e0174577.

29.

Mehta

Uchino

Fakhran

et al.

Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 2008; 39: 3236–3241.